Cardiovascular Diseases account for 25 % of total deaths in India
The 90-95 percent of CVD deaths happen due to coronary artery diseases . As per the report of National Commission on Macroeconomics and Health , prevalence of CAD in India is about 61.5 million as per 2015 report . As per Health Ministry report , more than 3.5 lakh procedures were done in 2015 which used 4.73 lakh stents . In 2016 , the figure of cardiac stent must have been above 5 lakhs . Presently market size of India made stents is roughly 30 percent .
While the govt acts tough on prices , industry is disappointed
The government says that new ceiling prices decided by it have considered interests of all the stakeholders , the medical technology industry in a much obvious reaction has called the price cap move as disappointing . While the medical device multinationals majority of whom are importers , are very much miffed at the order , the indigenous industry too feels that the action is bereft of any logic .
The Association of Indian Medical Device Manufacturers ( AIMeD ) had suggested the stent ’ s average price to hospitals to be the basis for arriving at a price band and had maintained that anything less than Rs 40,000- 50,000 for quality stents would be dampening and unfeasible commercially . Overtly concerned over the National Pharmaceutical Pricing Authority ’ s decision to fix stents prices at a level which defies economic logic or ground realities , Mr Rajiv Nath who is also the Forum Coordinator of the AiMeD stated , “ Regulations , however well intended , have to be reasonable and implementable with smooth transition and not disruptive . The worst thing about this notification is that NPPA / DPCO expect all stocks to be available at new price over night .”
Among the other big questions that AiMeD is asking are whether distributors have bought stents at Rs 60000 or so , how can they put MRP of Rs 30000 ? How can manufacturers recall stocks with 5 years shelf
BIOVOICENEWS . COM 19